Minerva Stock Analysis

NERV -  USA Stock  

USD 2.63  0.05  1.87%

The small fall in market price for the last few months may encourage sophisticated investors to take a closer look at the firm as it is trading at a share price of 2.63 on 468,000 in trading volume. The company directors and management did not add much value to Minerva Neuroscie investors in May. However, diversifying your holdings with Minerva Neuroscie or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.47. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Minerva Neuroscie partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

The Minerva Neuroscie stock analysis report makes it easy to digest most publicly released information about Minerva Neuroscie and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Minerva stock analysis module also helps to analyze the Minerva Neuroscie price relationship with some important fundamental indicators such as market cap and management efficiency.

Minerva Stock Analysis Notes

About 71.0% of the company shares are owned by institutional investors. The book value of Minerva Neuroscie was now reported as 1.23. The company had not issued any dividends in recent years. Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Minerva Neuroscie operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. To find out more about Minerva Neuroscie contact the company at 617 600-7373 or learn more at www.minervaneurosciences.com.

Minerva Neuroscie Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Minerva Neuroscie's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Minerva Neuroscie or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Minerva Neuroscie generates negative expected return over the last 90 days
Minerva Neuroscie has high historical volatility and very poor performance
Minerva Neuroscie has high likelihood to experience some financial distress in the next 2 years
Minerva Neuroscie currently holds about 25.36 M in cash with (33.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59.
Minerva Neuroscie has a poor financial position based on the latest SEC disclosures
Roughly 71.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Acquisition by Hans Hasler of 20000 shares of Minerva Neuroscie subject to Rule 16b-3

Minerva Neuroscie Upcoming and Recent Events

Earnings reports are used by Minerva Neuroscie to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Minerva Neuroscie previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report2nd of August 2021
Next Earnings Report1st of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End14th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Minerva Largest EPS Surprises

Earnings surprises can significantly impact Minerva Neuroscie's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Minerva Neuroscie SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Minerva Neuroscie prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Minerva Neuroscie investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Minerva Neuroscie specific information freely available to individual and institutional investors to make a timely investment decision.
19th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
16th of February 2021
Unclassified Corporate Event
12th of February 2021
Unclassified Corporate Event
10th of February 2021
Unclassified Corporate Event
8th of February 2021
Unclassified Corporate Event
29th of January 2021
Unclassified Corporate Event
19th of January 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
1st of December 2020
Financial Statements and Exhibits. Other Events

Minerva Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Minerva Neuroscie is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Minerva Neuroscie backward and forwards among themselves. Minerva Neuroscie's institutional investor refers to the entity that pools money to purchase Minerva Neuroscie's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Federated Hermes IncCommon Shares9.6 M28.1 M
Vanguard Group IncCommon Shares4.4 M12.9 M
Blackrock IncCommon Shares2.3 M6.8 M
Acadian Asset Management LlcCommon Shares1.7 M5.1 M
Dimensional Fund Advisors LpCommon Shares1.1 M3.2 M
Goldman Sachs Group IncCommon Shares955.9 K2.8 M
Morgan StanleyCommon Shares929.2 K2.7 M
Note, although Minerva Neuroscie's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Minerva Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 112.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Minerva Neuroscie's market, we take the total number of its shares issued and multiply it by Minerva Neuroscie's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Minerva Profitablity

Minerva Neuroscie's profitability indicators refer to fundamental financial ratios that showcase Minerva Neuroscie's ability to generate income relative to its revenue or operating costs. If, let's say, Minerva Neuroscie is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Minerva Neuroscie's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Minerva Neuroscie's profitability requires more research than a typical breakdown of Minerva Neuroscie's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 4.71 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of 4.49 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.04.
Last ReportedProjected for 2021
Return on Investment 4.13  4.11 
Return on Average Assets 0.03  0.0324 
Return on Average Equity 0.042  0.0453 
Return on Invested Capital 0.14  0.15 
Return on Sales 0.0423  0.0421 

Management Efficiency

The entity has return on total asset (ROA) of 1.71 % which means that it generated profit of $1.71 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.82 %, meaning that it created $4.82 on every $100 dollars invested by stockholders. Minerva Neuroscie management efficiency ratios could be used to measure how well minerva neuroscie manages its routine affairs as well as how well it operates its assets and liabilities. Minerva Neuroscie Return on Average Assets are fairly stable at the moment as compared to the past year. Minerva Neuroscie reported Return on Average Assets of 0.03 in 2020. Return on Average Equity is likely to climb to 0.0453 in 2021, whereas Return on Investment is likely to drop 4.11 in 2021. Minerva Neuroscie Total Assets are fairly stable at the moment as compared to the past year. Minerva Neuroscie reported Total Assets of 57.63 Million in 2020. Current Assets is likely to climb to about 28.2 M in 2021, whereas Net Current Assets as percentage of Total Assets are likely to drop 38.40 in 2021.
Last ReportedProjected for 2021
Book Value per Share 1.29  1.86 
Enterprise Value over EBIT 35.00  37.76 
Enterprise Value over EBITDA 31.84  34.35 
Price to Book Value 1.90  1.95 
Tangible Assets Book Value per Share 1.05  1.07 
Enterprise Value67.4 M69.2 M
Tangible Asset Value42.8 M43.9 M

Technical Drivers

As of the 19th of June, Minerva Neuroscie secures the mean deviation of 3.03, and Risk Adjusted Performance of (0.015148). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Minerva Neuroscie, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Minerva Neuroscie, which can be compared to its peers in the industry. Please verify Minerva Neuroscie standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Minerva Neuroscie is priced some-what accurately, providing market reflects its recent price of 2.63 per share. Please also check out Minerva Neuroscie total risk alpha, which is currently at (0.44) to check the company can sustain itself at a future point.

Minerva Neuroscie Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Minerva Neuroscie more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Minerva Neuroscie Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Minerva Neuroscie insiders, such as employees or executives, is commonly permitted as long as it does not rely on Minerva Neuroscie's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Minerva Neuroscie insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hans Hasler 3 days ago via Macroaxis 
Acquisition by Hans Hasler of 20000 shares of Minerva Neuroscie subject to Rule 16b-3
David Kupfer few days ago via Macroaxis 
Acquisition by David Kupfer of 20000 shares of Minerva Neuroscie subject to Rule 16b-3
Joseph Reilly over six months ago via Macroaxis 
Exercise or conversion by Joseph Reilly of 8750 shares of Minerva Neurosciences subject to Rule 16b-3
Devin Smith over six months ago via Macroaxis 
Acquisition by Devin Smith of 85000 shares of Minerva Neurosciences subject to Rule 16b-3
Race Geoff over six months ago via Macroaxis 
Acquisition by Race Geoff of 140000 shares of Minerva Neurosciences subject to Rule 16b-3
Van Heek G Jan over six months ago via Macroaxis 
Purchase by Van Heek G Jan of 7000 shares of Minerva Neurosciences
Devin Smith over six months ago via Macroaxis 
Acquisition by Devin Smith of 153531 shares of Minerva Neurosciences subject to Rule 16b-3
David Kupfer over a year ago via Macroaxis 
Acquisition by David Kupfer of 20000 shares of Minerva Neurosciences subject to Rule 16b-3
Frederick Ahlholm over a year ago via Macroaxis 
Sale by Frederick Ahlholm of 83 shares of Minerva Neurosciences
William Doyle over a year ago via Macroaxis 
Purchase by William Doyle of 2000 shares of Minerva Neurosciences
Care Capital Iii Llc over a year ago via Macroaxis 
Minerva Neurosciences exotic insider transaction detected
Fouzia LaghrissiThode over a year ago via Macroaxis 
Acquisition by Fouzia LaghrissiThode of 12500 shares of Minerva Neurosciences subject to Rule 16b-3

Minerva Neuroscie Predictive Daily Indicators

Minerva Neuroscie intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Minerva Neuroscie stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Minerva Neuroscie Forecast Models

Minerva Neuroscie time-series forecasting models is one of many Minerva Neuroscie's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Minerva Neuroscie's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Minerva Neuroscie Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Minerva Neuroscie stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Minerva shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Minerva Neuroscie. By using and applying Minerva Stock analysis, traders can create a robust methodology for identifying Minerva entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin 4.04  4.02 
EBITDA Margin 0.0459  0.0456 
Gross Margin 0.90  0.89 
Profit Margin 0.0423  0.0421 
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinsons disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Current Minerva Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Minerva analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Minerva analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Minerva Neuroscie current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Minerva analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Minerva stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Minerva Neuroscie, talking to its executives and customers, or listening to Minerva conference calls.
Minerva Analyst Advice Details

Minerva Stock Analysis Indicators

Minerva Neuroscie stock analysis indicators help investors evaluate how Minerva Neuroscie stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Minerva Neuroscie shares will generate the highest return on investment. By understating and applying Minerva Neuroscie stock analysis, traders can identify Minerva Neuroscie position entry and exit signals to maximize returns.
Quick Ratio8.02
Fifty Two Week Low2.1500
Shares Short Prior Month2.45M
Average Daily Volume Last 10 Day396.9k
Average Daily Volume In Three Month1.52M
Shares Percent Shares Out5.91%
Gross Margins46.47%
Short Percent Of Float8.35%
Forward Price Earnings-2.80
Float Shares41.14M
Fifty Two Week High4.1150
Enterprise Value To Ebitda39.65
Fifty Day Average2.8165
Two Hundred Day Average2.8905
Enterprise Value To Revenue1.79
Additionally, see Stocks Correlation. Note that the Minerva Neuroscie information on this page should be used as a complementary analysis to other Minerva Neuroscie's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Minerva Neuroscie Stock analysis

When running Minerva Neuroscie price analysis, check to measure Minerva Neuroscie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neuroscie is operating at the current time. Most of Minerva Neuroscie's value examination focuses on studying past and present price action to predict the probability of Minerva Neuroscie's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Minerva Neuroscie's price. Additionally, you may evaluate how the addition of Minerva Neuroscie to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Correlations
Find global opportunities by holding instruments from different markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
The market value of Minerva Neuroscie is measured differently than its book value, which is the value of Minerva that is recorded on the company's balance sheet. Investors also form their own opinion of Minerva Neuroscie's value that differs from its market value or its book value, called intrinsic value, which is Minerva Neuroscie's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Minerva Neuroscie's market value can be influenced by many factors that don't directly affect Minerva Neuroscie underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Minerva Neuroscie's value and its price as these two are different measures arrived at by different means. Investors typically determine Minerva Neuroscie value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Minerva Neuroscie's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.